Mazindol


Concise Prescribing Info
Indications/Uses
Obesity.
Dosage/Direction for Use
Adult : PO Initial: 0.5-1 mg/day in the morning, up to 1.5-2 mg/day after 1 wk if needed. Max: 3 mg/day in divided doses. Duration: Usual: 4-6 wk; max: 12 wk.
Dosage Details
Oral
Obesity
Adult: Initially, 0.5-1 mg/day in the morning. May increase to 1.5-2 mg/day after 1 wk, depending on patient's response. Max dose: 3 mg/day in divided doses. Treatment duration: 4-6 wk. Max: 12 wk.
Child: >12 yr: Initially, 0.5-1 mg/day in the morning. May increase to 1.5-2 mg/day after 1 wk, depending on patient's response. Max dose: 3 mg/day in divided doses. Treatment duration: 4-6 wk. Max: 12 wk.
Administration
Should be taken with food.
Contraindications
Narrow-angle glaucoma; severe renal or hepatic impairment; cerebrovascular or CV disease, pulmonary artery hypertension, severe arterial hypertension, anorexia nervosa, depression, hyperexcitability and agitation, history of or predisposition to drug abuse, known alcoholism. Lactation. Children <12 yr.
Special Precautions
DM, psychosis, epilepsy, prolonged treatment. Ensure gradual and controlled wt loss in obese patients. Cardiac murmur or cardiac valve abnormalities. May impair ability to drive or operate machinery. Elderly. Pregnancy.
Adverse Reactions
Nervousness, agitation, dizziness, drowsiness, depression, psychosis, vertigo, insomnia, dryness of mouth, headache, tremor, hallucination, paraesthesia, anxiety, convulsion, tachycardia, palpitation, precordial pain, hypertension, pulmonary artery hypertension, diarrhoea, taste disturbance, asthenia, skin reaction, sexual dysfunction, menstrual disorder, sweating, flushing, dysuria.
Drug Interactions
Additive effects with other centrally acting anorectics. Significant hypertension with MAOIs. Increased risk of lithium toxicity.
Action
Description: Mazindol is a central stimulant which acts by inhibiting the reuptake of dopamine and noradrenaline. It has been used as an anorectic in the treatment of obesity but stimulants are no longer recommended for this indication.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract.
Excretion: Via urine (as metabolite and unchanged drug).
Storage
Store at room temperature.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Mazindol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in